Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage biotechnology company focused on immuno-inflammatory diseases and leveraging the US-India innovation corridor, has announced its first full financial results as a publicly traded company following its Nasdaq listing. The company reported strong progress across clinical development, operational efficiency, and financial stability during its first quarter as a public entity. Krishna Gupta, Chairman of Vyome, emphasized the company’s strategic focus on addressing inflammation—a key driver behind numerous medical and mental health conditions. He highlighted the company’s unique positioning across the US-India innovation ecosystem as a major competitive advantage. “We had a great first quarter as a public company thanks to our distinct strengths, including access to top-tier talent and innovation hubs on both sides of the Atlantic,” Gupta said. He pointed to the positive interim results from Vyome’s lead program, VT-1953, as a pivotal milestone in tackling a significant unmet medical need. Venkat Nelabhotla, CEO of Vyome, noted that the company executed a highly efficient transition to the public markets, achieving its goals while spending less cash than anticipated. “We are advancing our lead program with disciplined operations, a clean capital structure, and a world-class team,” Nelabhotla said. “The promising interim Phase 2 data for VT-1953 reinforces the scientific potential of our immuno-inflammation platform.” VT-1953, a topical treatment for malignant fungating wounds (MFW), is showing strong clinical momentum. MFW affects 5–14% of advanced cancer patients and causes severe physical and emotional distress due to intense odor and pain. With no FDA-approved treatment currently available, the condition represents a $1 billion addressable market in the U.S. alone. VT-1953 is being developed as a potential orphan drug, with full Phase 2 data expected in early December 2025. In addition, Vyome reported continued progress with VT-1908, a topical eye drop candidate for uveitis. Preclinical data from the third quarter demonstrated strong efficacy in uveitis models, supporting its potential as a steroid-sparing therapy. The company plans to engage with the FDA in the first half of 2026 and advance the program toward clinical trials. Financially, Vyome reported a significant improvement in its balance sheet. As of September 30, 2025, the company held $5.7 million in cash and cash equivalents, up from $101,904 at the end of 2024. Total assets reached $7.0 million, compared to $1.4 million in 2024. The company’s total stockholders’ equity improved to $3.9 million, reversing a prior deficit of $4.4 million. Vyome will host a conference call on Thursday, November 20, at 10:00 a.m. ET to discuss the results. Investors can join via webcast or phone. The company reaffirmed its commitment to delivering long-term value to shareholders while advancing transformative therapies for patients with inflammatory conditions.